Bookbuilding IPO | ₹25 Cr | Listed at BSE SME
Accretion Nutraveda IPO is a book build issue of ₹24.77 crores. The issue is entirely a fresh issue of 0.19 crore shares of ₹24.77 crore.
Accretion Nutraveda IPO bidding started from Jan 28, 2026 and ended on Jan 30, 2026. The allotment for Accretion Nutraveda IPO was finalized on Feb 2, 2026. The shares got listed on BSE SME on Feb 4, 2026.
Accretion Nutraveda IPO price band is set at ₹129 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,87,000.
Sobhagya Capital Options Pvt.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Sunflower Broking Pvt.Ltd..
Refer to Accretion Nutraveda IPO RHP for detailed Information.
IPO Open
Wed, Jan 28, 2026
IPO Close
Fri, Jan 30, 2026
Issue Price
₹129 per share
Market Cap (Pre-IPO)
₹93.40 Cr
| IPO Date | 28 to 30 Jan, 2026 |
| Listed on | Wed, Feb 4, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹122 to ₹129 |
| Issue Price | ₹129 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 19,20,000 shares (agg. up to ₹25 Cr) |
| Reserved for Market Maker | 96,000 shares Sunflower Broking Pvt.Ltd. (agg. up to ₹1 Cr) |
| Net Offered to Public | 18,24,000 shares (agg. up to ₹24 Cr) |
| Share Holding Pre Issue | 53,20,000 shares |
| Share Holding Post Issue | 72,40,000 shares |
| BSE Script Code | 544694 |
| ISIN | INE1KVQ01019 |
Accretion Nutraveda IPO offers total 19,20,000 shares. Out of which 9,08,000 (47.29%) allocated to QIB, 3,64,000 (18.96%) allocated to QIB (Ex- Anchor), 2,76,000 (14.37%) allocated to NII 6,40,000 (33.33%) allocated to RII and 5,44,000 (28.33%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 96,000 (5.00%) |
| QIB Shares Offered | 9,08,000 (47.29%) |
| − Anchor Investor Shares Offered | 5,44,000 (28.33%) |
| − QIB (Ex. Anchor) Shares Offered | 3,64,000 (18.96%) |
| NII (HNI) Shares Offered | 2,76,000 (14.37%) |
| − bNII > ₹10L | 1,84,000 (9.58%) |
| − sNII < ₹10L | 92,000 (4.79%) |
| Retail Shares Offered | 6,40,000 (33.33%) |
| Total Shares Offered | 19,20,000 (100.00%) |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,32,000 |
Accretion Nutraveda IPO raises ₹7.02 crore from anchor investors. Accretion Nutraveda IPO Anchor bid date is January 27, 2026.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, Jan 27, 2026 |
| Shares Offered | 5,44,000 |
| Anchor Portion (₹ Cr.) | 7.02 |
| Anchor lock-in period end date for 50% shares (30 Days) | Tue, Mar 3, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sat, May 2, 2026 |
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.
The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Business verticals:
It has a manufacturing facility in Gujarat covers about 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, separate processing areas, and quality control systems. The facility is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified, with an FSSAI license.
Competitive Strengths
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| 2 | Purchase of Machineries for New Manufacturing Setup | 8.03 |
| 3 | Funding working capital requirements of our company | 5.50 |
| 4 | General corporate purposes | 3.69 |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 68.54% | 81.22% |
| ROCE | 49.09% | 36.98% |
| Debt/Equity | 0.54 | 0.72 |
| RoNW | 56.50% | 48.85% |
| PAT Margin | 16.59% | 16.33% |
| EBITDA Margin | 23.36% | 22.79% |
| Price to Book Value | 7.71 | 8.76 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 4.91 | 6.44 |
| P/E (x) | 26.27 | 20.02 |
| Promoter Holding | 100% | 73.48% |
| Market Cap | ₹93.40 Cr. |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manger fees | 0.25 |
| 2 | Fees Payable to Registrar to the Issue | 0.02 |
| 3 | Fees Payable for Advertising and Publishing Expenses | 0.25 |
| 4 | Fees Payable to Regulators including Stock Exchanges | 0.04 |
| 5 | Payment for Printing & Stationery, Postage, etc. | 0.01 |
| 6 | Fees Payable to Auditor, Legal Advisors and other Professionals | 0.02 |
| 7 | Others, if any (Fees payable for Marketing & distribution expenses, Selling Commission, Brokerage, depositories, secretarial, advisors, consultancy, peer review auditors, Processing Fees, Underwriting fees and Miscellaneous Expenses) | 2.74 |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹129.00 |
| Open | ₹191.00 |
| Low | ₹190.50 |
| High | ₹200.55 |
| Last Trade | ₹191.20 |
Lead Manager Reports
Accretion Nutraveda IPO is a SME IPO of 19,20,000 equity shares of the face value of ₹10 aggregating up to ₹25 Crores. The issue is priced at ₹129 per share. The minimum order quantity is 1000.
The IPO opens on Wed, Jan 28, 2026, and closes on Fri, Jan 30, 2026.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Accretion Nutraveda IPO using UPI as a payment gateway. Zerodha customers can apply in Accretion Nutraveda IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Accretion Nutraveda IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Accretion Nutraveda IPO opens on Wed, Jan 28, 2026 and closes on Fri, Jan 30, 2026.
Accretion Nutraveda IPO lot size is 1000, and the minimum amount required for application is ₹2,58,000, with 2 lots being the minimum application size.
You can apply in Accretion Nutraveda IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Accretion Nutraveda IPO will be done on Monday, February 2, 2026, and the allotted shares will be credited to your demat account by Tue, Feb 3, 2026. Check the Accretion Nutraveda IPO allotment status.
The Accretion Nutraveda IPO listing date is on Wed, Feb 4, 2026.
